

23 November 2016

ASX ANNOUNCEMENT

Annual General Meeting – Amendment to Resolutions

The Annual General Meeting of Bioxyne Limited (ASX: BXN) will be held on Thursday 24 November at 12 noon at the Boardroom of RSM Australia Level 13, 60 Castlereagh Street, Sydney.

The Board advises that Resolution 4 of the Notice of Meeting lodged with the ASX on 24 October 2016 will not be put to the meeting, and will be dealt at a subsequent shareholders meeting.

Guy Robertson
Company Secretary

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian life sciences, health and medical technologies company (originated as VRI Biomedical Ltd in 2000) with a focus on immune health and immunotherapeutic products.

Bioxyne has a strategic investment in the consumer dietary supplements and functional foods markets through its proprietary probiotic, *Lactobacillus fermentum* PCC®. Bioxyne is a company creating value for consumers and investors by delivering safe and effective solutions.

Bioxyne's focus is currently on the company's probiotic business and proprietary product *Lactobacillus fermentum* PCC® which is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne also has a distribution agreement with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who pride themselves in offering only quality solutions to their customers.

Tony Ho
Non-executive Chairman
Mob: +61 417 345 839

Guy Robertson
Chief Operating Officer
Mob: +61 407 983 270